Harvey J, Wing RR, Mullen M
Although Amgen did not disclose many details, management was encouraged enough to announce that the program will move to phase 3 in obesity, obesity-related indications, and diabetes, an area where theoretical concerns about blood sugar effects of the drug had previously made development less appealing
BFH publishes press releases for the global Direct Selling / Network Marketing / Home Business community
Data Availability The datasets used and/or analyzed during this study are available from the corresponding author on reasonable request
Our Experts Weigh In Weight and Health Benefits Vanish Fast After Quitting Weight-Loss Drugs, Study Finds Scientific American : Massachusetts General Hospital: Preserving Lean Body Mass in Patients Taking GLP-1 for Weight Loss Swartz AZ et al
Tingling or pins and needles may precede normal feeling